Approval Recommended For Dendreon's Provenge

After reviewing data on Dendreon Corp.'s (DNDN) Provenge, an FDA advisory committee recommended approval for the prostate cancer treatment. Shares of the biotechnology company more than doubled by leaping $7.71 to close at $12.93.